Clinical trials
Thyroid Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 6 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Central Hospital, Nancy, France | 2 |
| Centre Francois Baclesse | 2 |
| Centre Hospitalier Universitaire, Amiens | 2 |
| Hospices Civils de Lyon | 2 |
| IHU Strasbourg | 2 |
| CHU de Reims | 1 |
| Centre Hospitalier Régional d'Orléans | 1 |
| Fondation Lenval | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Diseases | 29 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Endocrine Gland Neoplasms | 5 |
| Head and Neck Neoplasms | 5 |
| Neoplasms | 5 |
| Thyroid Neoplasms | 5 |
| Bronchial Neoplasms | 4 |
| Carcinoma, Bronchogenic | 4 |
| Carcinoma, Medullary | 4 |
| Colonic Neoplasms | 4 |
Trials
Showing 76 to 29 of 29. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.